- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Emcure wins dismissal of US lawsuit over COVID vaccine trade secrets
The lawsuit said that HDT licensed its technology to Emcure subsidiary Gennova Biopharmaceuticals to develop and sell the vaccine in India. HDT accused Genova of later claiming the vaccine "as its own," applying for two Indian patents on HDT's technology and touting the "indigenously developed" shots in regulatory filings.
Generic drugmaker Emcure Pharmaceuticals convinced a federal court in Seattle, Washington, on Monday to throw out a lawsuit that accused it of stealing trade secrets from biopharma company HDT Bio to develop a COVID-19 vaccine.
A sealed entry in the court's docket said that U.S. District Judge James Robart dismissed the case without prejudice, which means it can be refiled. India-based Emcure had argued that the court lacked jurisdiction over the company.
Representatives for HDT did not immediately respond to a request for comment. A spokesperson for Emcure said on Tuesday morning that the ruling "vindicates our stand."
Seattle-based HDT sued Emcure last year. It said in the lawsuit that it was developing a self-amplyifing RNA (saRNA) shot for COVID-19 that is "safer, cheaper, more portable, and likely more effective" than existing mRNA vaccine technology.
The lawsuit said that HDT licensed its technology to Emcure subsidiary Gennova Biopharmaceuticals to develop and sell the vaccine in India. HDT accused Gennova of later claiming the vaccine "as its own," applying for two Indian patents on HDT's technology and touting the "indigenously developed" shots in regulatory filings.
HDT's lawsuit said that Gennova refused to pay royalties and broke their licensing agreement, requesting at least $950 million in monetary damages. It has also filed a related complaint with the London Court of International Arbitration.
Gennova's COVID-19 vaccine was approved for emergency use by the Indian government last June.
Emcure argued in September that the court lacked jurisdiction over the company because it has no business presence in the United States, and that it and Gennova are "unquestionably distinct separate entities."
"This is an illegitimate lawsuit brought by a company using litigation to compensate for its business shortcomings," Emcure said.
The case is HDT Bio Corp v. Emcure Pharmaceuticals Ltd, U.S. District Court for the District of Washington, No. 2:22-cv-00334.
For HDT: Peter Stris, Dana Berkowitz, Kenneth Halpern and John Stokes of Stris & Maher
For Emcure: James Sanders, Amanda Beane and Eric Wolff of Perkins Coie
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751